menu
    • menu

    Company profile for Cerevel Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cerevel Therapeutics relentlessly finds paths through complexity to bring real progress and new treatment options to people living with a broad range of neurological and neuropsychiatric disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cerevel TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cerevel Therapeutics, LLC 131 Dartmouth St, Suite 502 Boston, MA 02116
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cerevel.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bristol’ schizophrenia drug nears approval, AbbVie hope to provide competition
    Bristol’ schizophrenia drug nears approval, AbbVie hope to provide competition

    19 Aug 2024

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/bms-karxt-schizophrenia-approval-abbvie/724555/

    BIOPHARMADIVE
    19 Aug 2024
    Share Share
    AbbVie Completes Acquisition of Cerevel Therapeutics
    AbbVie Completes Acquisition of Cerevel Therapeutics

    01 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-cerevel-therapeutics-302212336.html

    PR NEWSWIRE
    01 Aug 2024
    Share Share
    Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
    Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

    19 Apr 2024

    // Ned Pagliarulo BIOPHARMADIVE

    https://www.biopharmadive.com/news/cerevel-parkinsons-tavapadon-study-results-abbvie/713566/

    Ned Pagliarulo BIOPHARMADIVE
    19 Apr 2024
    Share Share
    Cerevel's Tavapadon Meets Phase 3 Adjunctive Parkinson's Trial Goals
    Cerevel's Tavapadon Meets Phase 3 Adjunctive Parkinson's Trial Goals

    18 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/18/2865216/0/en/Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-Tavapadon-in-Phase-3-Adjunctive-Trial-for-People-Living-with-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    18 Apr 2024
    Share Share
    Cerevel Therapeutics is lower by 3.66% Tuesday In Premarket Trading
    Cerevel Therapeutics is lower by 3.66% Tuesday In Premarket Trading

    01 Feb 2024

    // INVESTOR OBSERVER

    https://www.investorsobserver.com/news/stock-update/cerevel-therapeutics-holdings-inc-cere-is-lower-by-3-66-tuesday-in-premarket-trading

    INVESTOR OBSERVER
    01 Feb 2024
    Share Share
    AbbVie to acquire Cerevel for $8.7 billion
    AbbVie to acquire Cerevel for $8.7 billion

    07 Dec 2023

    // Ananya M. Rajesh REUTERS

    https://www.reuters.com/markets/deals/abbvie-buy-drug-developer-cerevel-87-billion-2023-12-06/

    Ananya M. Rajesh REUTERS
    07 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search